JP2010530892A5 - - Google Patents

Download PDF

Info

Publication number
JP2010530892A5
JP2010530892A5 JP2010513439A JP2010513439A JP2010530892A5 JP 2010530892 A5 JP2010530892 A5 JP 2010530892A5 JP 2010513439 A JP2010513439 A JP 2010513439A JP 2010513439 A JP2010513439 A JP 2010513439A JP 2010530892 A5 JP2010530892 A5 JP 2010530892A5
Authority
JP
Japan
Prior art keywords
compressed tablet
total weight
tablet
ritonavir
intragranular lubricant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2010513439A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010530892A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2008/067633 external-priority patent/WO2009002829A2/en
Publication of JP2010530892A publication Critical patent/JP2010530892A/ja
Publication of JP2010530892A5 publication Critical patent/JP2010530892A5/ja
Pending legal-status Critical Current

Links

JP2010513439A 2007-06-22 2008-06-20 アタザナビルを含む錠剤組成物 Pending JP2010530892A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US94569407P 2007-06-22 2007-06-22
PCT/US2008/067633 WO2009002829A2 (en) 2007-06-22 2008-06-20 Tableted compositions containing atazanavir

Publications (2)

Publication Number Publication Date
JP2010530892A JP2010530892A (ja) 2010-09-16
JP2010530892A5 true JP2010530892A5 (enExample) 2011-07-28

Family

ID=39645403

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010513439A Pending JP2010530892A (ja) 2007-06-22 2008-06-20 アタザナビルを含む錠剤組成物

Country Status (17)

Country Link
US (2) US20100183716A1 (enExample)
EP (1) EP2178513B1 (enExample)
JP (1) JP2010530892A (enExample)
KR (1) KR20100033377A (enExample)
CN (1) CN101795674A (enExample)
AT (1) ATE503467T1 (enExample)
AU (1) AU2008268537B2 (enExample)
CY (1) CY1111957T1 (enExample)
DE (1) DE602008005896D1 (enExample)
DK (1) DK2178513T3 (enExample)
ES (1) ES2361796T3 (enExample)
HR (1) HRP20110294T1 (enExample)
MX (1) MX2009013461A (enExample)
PL (1) PL2178513T3 (enExample)
PT (1) PT2178513E (enExample)
SI (1) SI2178513T1 (enExample)
WO (1) WO2009002829A2 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2178512B1 (en) * 2007-06-22 2011-03-09 Bristol-Myers Squibb Company Tableted compositions containing atazanavir
WO2009056818A1 (en) * 2007-10-29 2009-05-07 Cipla Limited Novel antiretroviral combination
WO2010064611A1 (ja) 2008-12-01 2010-06-10 武田薬品工業株式会社 複素環化合物およびその用途
US10071059B2 (en) * 2009-12-18 2018-09-11 Frieslandcampina Nederland Holding B.V. Co-processed tablet excipient composition its preparation and use
US20130203759A1 (en) 2010-04-09 2013-08-08 Faranak Nikfar ATAZANAVIR SULFATE FORMULATIONS WITH IMPROVED pH EFFECT
BR112015006558A2 (pt) 2012-10-23 2017-07-04 Cipla Ltd composição farmacêutica, processo para preparar uma composição farmacêutica, uso de uma composição farmacêutica, e, método para prevenir ou tratar doenças causadas por retrovírus
MX2016002560A (es) * 2013-08-29 2016-10-26 Teva Pharma Forma de dosificacion unitaria que comprende emtricitabina, tenofovir, darunavir y ritonavir y un comprimido monolitico que comprende darunavir y ritonavir.
CN104784133A (zh) * 2014-01-19 2015-07-22 广东东阳光药业有限公司 一种齐多夫定的片剂及其制备方法
KR101669240B1 (ko) * 2015-03-12 2016-10-25 아주대학교산학협력단 테노포비어 디소프록실 유리염기를 포함하는 정제 및 이의 제조방법
CA2937365C (en) 2016-03-29 2018-09-18 F. Hoffmann-La Roche Ag Granulate formulation of 5-methyl-1-phenyl-2-(1h)-pyridone and method of making the same
GB201800249D0 (en) * 2018-01-08 2018-02-21 Univ Of Sussex Pickering emulsions

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2940998A (en) * 1953-10-15 1960-06-14 Ajinomoto Kk Process for resolution of racemic glutamic acid and salts thereof
GB919491A (en) * 1958-12-23 1963-02-27 Ici Ltd Pharmaceutical compositions
US4026897A (en) * 1974-01-31 1977-05-31 Otsuka Pharmaceutical Company 5-[1-Hydroxy-2-(substituted-amino)]alkyl-8-hydroxycarbostyril derivatives
US3980637A (en) * 1975-03-17 1976-09-14 Bristol-Myers Company Production of amoxicillin
US4556654A (en) * 1983-06-28 1985-12-03 Warner-Lambert Company Antimicrobial substituted anthra[1,9-cd]pyrazol-6(2H)-ones
DE3403329A1 (de) * 1984-02-01 1985-08-01 Horst Dr. 4019 Monheim Zerbe Pharmazeutisches produkt in form von pellets mit kontinuierlicher, verzoegerter wirkstoffabgabe
FR2623810B2 (fr) * 1987-02-17 1992-01-24 Sanofi Sa Sels de l'alpha-(tetrahydro-4,5,6,7 thieno(3,2-c) pyridyl-5) (chloro-2 phenyl) -acetate de methyle dextrogyre et compositions pharmaceutiques en contenant
US5158777A (en) * 1990-02-16 1992-10-27 E. R. Squibb & Sons, Inc. Captopril formulation providing increased duration of activity
CA2068402C (en) * 1991-06-14 1998-09-22 Michael R. Hoy Taste mask coatings for preparation of chewable pharmaceutical tablets
US5753652A (en) * 1991-07-03 1998-05-19 Novartis Corporation Antiretroviral hydrazine derivatives
CA2103932A1 (en) * 1992-11-05 1994-05-06 Ramesh N. Patel Stereoselective reduction of ketones
US5461067A (en) * 1993-02-25 1995-10-24 Abbott Laboratories Retroviral protease inhibiting compounds
US5428048A (en) * 1993-11-08 1995-06-27 American Home Products Corporation Aryl-N-hydroxyureas as inhibitors of 5-lipoxygenase and anto-arteriosclerotic agents
GB9407386D0 (en) * 1994-04-14 1994-06-08 Smithkline Beecham Plc Pharmaceutical formulation
UA49803C2 (uk) * 1994-06-03 2002-10-15 Дж.Д. Сьорль Енд Ко Спосіб лікування ретровірусних інфекцій
TW483763B (en) * 1994-09-02 2002-04-21 Astra Ab Pharmaceutical composition comprising of ramipril and dihydropyridine compound
JP3529904B2 (ja) * 1995-06-19 2004-05-24 鐘淵化学工業株式会社 光学活性１−ハロ−３−アミノ−４−フェニル−２−ブタノール誘導体の製造法
US6037157A (en) * 1995-06-29 2000-03-14 Abbott Laboratories Method for improving pharmacokinetics
US5750493A (en) * 1995-08-30 1998-05-12 Raymond F. Schinazi Method to improve the biological and antiviral activity of protease inhibitors
US5767316A (en) * 1995-11-17 1998-06-16 Ajinomoto Co., Inc. Process for producing 3-amino-2-oxo-1-halogenopropane derivatives
US5849911A (en) * 1996-04-22 1998-12-15 Novartis Finance Corporation Antivirally active heterocyclic azahexane derivatives
US6087383A (en) * 1998-01-20 2000-07-11 Bristol-Myers Squibb Company Bisulfate salt of HIV protease inhibitor
US6737264B1 (en) * 1999-01-21 2004-05-18 Kaneka Corporation Method for purifying and isolating (2s,3s)- or (2r,3s)-halohydrin derivatives
EP1067125B1 (en) * 1999-01-29 2006-07-26 Kaneka Corporation PROCESSES FOR THE PREPARATION OF threo-1,2-EPOXY-3-AMINO-4-PHENYLBUTANE DERIVATIVES
JP2002540102A (ja) * 1999-03-22 2002-11-26 ブリストル−マイヤーズ スクイブ カンパニー ｃＧＭＰホスホジエステラーゼの縮合ピリドピリダジン阻害剤
US6605732B1 (en) * 1999-05-03 2003-08-12 Aerojet Fine Chemicals Llc Clean, high-yield preparation of S,S and R,S amino acid isosteres
KR100708221B1 (ko) * 1999-08-31 2007-04-17 아지노모토 가부시키가이샤 에폭사이드 결정의 제조방법
US6399393B1 (en) * 1999-09-21 2002-06-04 The United States Of America As Represented By The Department Of Energy Cryogenic homogenization and sampling of heterogeneous multi-phase feedstock
US6414002B1 (en) * 1999-09-22 2002-07-02 Bristol-Myers Squibb Company Substituted acid derivatives useful as antidiabetic and antiobesity agents and method
US6254888B1 (en) * 2000-01-28 2001-07-03 Boehringer Ingelheim Pharmaceuticals, Inc. Method for coating pharmaceutical dosage forms
US6395767B2 (en) * 2000-03-10 2002-05-28 Bristol-Myers Squibb Company Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method
CZ20011726A3 (cs) * 2000-05-26 2002-02-13 Pfizer Products Inc. Způsob reakční krystalizace, který umoľňuje řídit velikost částic
WO2002014528A1 (en) * 2000-08-16 2002-02-21 Bristol-Myers Squibb Company Stereoselective reduction of substituted oxo-butanes
IL145106A0 (en) * 2000-08-30 2002-06-30 Pfizer Prod Inc Intermittent administration of a geowth hormone secretagogue
US6670344B2 (en) * 2000-09-14 2003-12-30 Bristol-Myers Squibb Company Combretastatin A-4 phosphate prodrug mono- and di-organic amine salts, mono- and di- amino acid salts, and mono- and di-amino acid ester salts
KR20020046948A (ko) * 2000-12-12 2002-06-21 에가시라 구니오 에폭사이드 결정의 제조방법
HRP20040181A2 (en) * 2001-08-31 2004-08-31 Bristol Myers Squibb Co Use of atazanavir in hiv therapy
KR100933625B1 (ko) * 2001-09-04 2009-12-24 다우 글로벌 테크놀로지스 인크. 수성 에어 포움, 이를 사용한 고체 입자의 응집방법 및 피복방법
US7384734B2 (en) * 2002-02-15 2008-06-10 Monogram Biosciences, Inc. Compositions and methods for determining the susceptibility of a pathogenic virus to protease inhibitors
KR100456833B1 (ko) * 2002-08-01 2004-11-10 주식회사 대웅 아목시실린 및 클라불라네이트를 함유하는 유핵정
FR2855756B1 (fr) * 2003-06-06 2005-08-26 Ethypharm Sa Comprime orodispersible multicouche
US20050148523A1 (en) * 2003-12-15 2005-07-07 Colonno Richard J. Method of treating HIV infection in atazanavir-resistant patients using a combination of atazanavir and another protease inhibitor
TW200534879A (en) * 2004-03-25 2005-11-01 Bristol Myers Squibb Co Coated tablet formulation and method
US20050256314A1 (en) * 2004-05-04 2005-11-17 Soojin Kim Process employing controlled crystallization in forming crystals of a pharmaceutical
US7829720B2 (en) * 2004-05-04 2010-11-09 Bristol-Myers Squibb Company Process for preparing atazanavir bisulfate and novel forms
US20050288343A1 (en) * 2004-05-19 2005-12-29 Andrew Rusowicz Process of preparing substituted carbamates and intermediates thereof
TWI415635B (zh) * 2004-05-28 2013-11-21 必治妥施貴寶公司 加衣錠片調製物及製備彼之方法
AR045841A1 (es) * 2004-09-28 2005-11-16 Richmond Sa Com Ind Y Financie Una composicion farmaceutica solida que comprende al tiazolil metil ester del acido [5s-(5r*, 8r*, 10r*,11r*)] -10- hidroxi-2- metil-5-(1-metiletil)-1-[2-(1-metiletil)-4-tiazolil]-3,6-dioxo-8,11-bis(fenilmetil)-2,4,7,12- tetraazatridecan-13-oico y un procedimiento para prepararla.
US7582468B2 (en) * 2005-05-25 2009-09-01 Bristol-Myers Squibb Company Process for preparing (2R,3S)-1,2-epoxy-3-(protected)amino-4-substituted butane and intermediates thereof
US20070059360A1 (en) * 2005-07-29 2007-03-15 Ashish Jaiswal Water-dispersible anti-retroviral pharmaceutical compositions

Similar Documents

Publication Publication Date Title
JP2010530889A5 (enExample)
JP2010530892A5 (enExample)
HRP20110294T1 (hr) Smjese u obliku tablete koje sadržavaju atazanavir
UY27995A1 (es) Nuevas formulaciones farmacéuricas solidas que comprenden telmartisano y su preparación
JP2012197280A5 (enExample)
EA023807B1 (ru) Устойчивые оральные фармацевтические дозированные формы, содержащие опиоидный анальгетик
HRP20140146T1 (hr) Smjese koje sadrže atazanavir oblikovane u tablete
RU2017133990A (ru) Фармацевтические лекарственные формы ингибитора тирозинкиназы брутона
JP2010530890A5 (enExample)
NZ605469A (en) Nalbuphine-based formulations and uses thereof
HRP20161262T1 (hr) Tablete ulipristal acetata
HRP20250604T1 (hr) Formulacije tableta neratinib maleata
JP2007523210A5 (enExample)
RU2017134002A (ru) Стабильные композиции тетрагидробиоптерина
BR112012019374A2 (pt) composição farmacêutica, pellet de liberação prolongada, composição farmacêutica oral, método para tratamento de uma doença neurodegenerativa ou um dano ao sistema nervoso em um indivíduo necessitado do mesmo e método para preparação de uma formulação de liberação prolongada de um agente ativo
JP2010522240A5 (enExample)
JP2010083886A (ja) 経口投与用粒子状医薬組成物
US20090317465A1 (en) Composition and method of preparation of release systems for constant (zero-order) release of active agents
RU2014115287A (ru) Фармацевтическая композиция для перорального введения с маскированным вкусом и способ ее получения
JP2011525501A5 (enExample)
WO2010020856A3 (en) Rate modulated delivery of drugs from a composite delivery system
HRP20130123T1 (hr) Postupak lijeäśenja bolesti
WO2007134158A3 (en) Granules comprising calcium carbonate, a binder and a porosity increasing agent, processes of manufacturing, use in therapy
HRP20151347T1 (hr) Nova kombinacija
HRP20190550T1 (hr) Formule i metode proizvodnje formulacija za upotrebu u pražnjenju debelog crijeva